 |
|---|
|
International Consoldiated Companies Appoints ODL Securities to Raise up to US $50 MillionInternational Consolidated Companies, Inc. (OTCBB: INCC) specializes in acquiring international businesses, located in rapidly expanding Asian markets focused on three dynamic areas: healthcare, technology and the environment. Utilizing a unique acquisition model INCC provides foreign companies an opportunity to gain access to U.S. capital markets. In exchange, INCC retains a significant percentage of each target company, creating a diversified, growth oriented investment base that should enjoy a steady, long-term increase. Each target company reviewed for acquisition must meet specific criteria detailed in INCC’s acquisition model and have a proven commercial track record.
Why Invest In International Consolidated Companies, Inc.?International Consolidated Companies, Inc. has developed an acquisition model that enables the Company to increase shareholder value while minimizing management costs associated with each transaction. The initial acquisition will enable International Consolidated Companies, Inc. to begin the development of a strong, diversified healthcare subsidiary that will be the cornerstone of the three areas identified in the Company's mission statement. The healthcare industry, especially the areas that have been targeted, combating cancers for biological treatment, curing cervical cancer and curing chronic Hepatitis B and C, is an area of immense opportunity and growth. Acquisition ProfileThe initial market that INCC has entered is bio-tech pharmaceuticals and bioengineered medicines. China’s pharmaceutical sector has maintained steady growth over the past few years with revenues moving to $54.6 billion, up nearly 26% last year. A major acquisition for the Company is China Gene, Ltd. (Hong Kong) – which has two subsidiaries: Shanghai Huaxin High Biotechnology, Inc. and Sichuan Kelun Bio-Tech Pharmaceutical Company. Shanghai Huaxin High Biotechnology, Inc. has patents on a proprietary delivery system for the drug Interferon - used to fight Hepatitis B and C (the two single largest killers in China) and Cervical Cancer. According to Hong Kong Pharmaceutical Holdings Limited, Shanghai Huaxin is considered to be the first biotechnology enterprise and the birthplace of the first bioengineered medicine in China. Sichuan Kelun Bio-Tech Pharmaceutical Company specializes in gene-tech and biotech products. The company is an “exporter” of antisera (a serum containing antibodies; an antitoxin) and other blood fractions, vaccines and toxins. Its main products are: biologic products, blood products, plant extracts, chemical pharmaceuticals and anti-cancer products. China Gene, Ltd. (Hong Kong) at 6/30/07 had consolidated total sales of $3.1 million; consolidated net income of $800,000; consolidated total assets of $13.1 million; and consolidated total liabilities of $7.2 million as reported by the Company's auditors, Bagell, Josephs, Levine & Company, LLC. Investment Considerations and Summary
|
|---|
SmallCapVoice.com is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities members should buy or sell for themselves. Members should always check with their licensed financial advisor and their tax advisor to determine the suitability of any investment. This Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover this publication accepts compensation from some of the companies which it features. For compensation and complete disclaimer click here.